Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMVT
SellHot AirImmunovant, Inc. · Healthcare · United States · $8.5B · Avg Vol: $44M/d
COMPANY DESCRIPTION
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapies for patients with autoimmune diseases. The company's lead investigational product, batoclimab, is a novel FcRn inhibitor designed to reduce pathogenic IgG antibodies that drive a broad range of autoimmune conditions. Its competitive position hinges on the potential for batoclimab to become a best-in-class treatment across multiple indications with high unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 36.8M | — |
| EPS | -1.43 | -1.71 | -1.88 | -2.73 | -2.48 | — | -2.81 | -2.84 | -2.75 | — |
| Shares | — | 130.3M | 145.6M | 170.1M | 203.9M | +56.5% | 206.6M | — | — | — |
| Debt | — | 1.2M | 0.1M | 98.0K | 72.0K | -61.1% | — | — | — | — |
| Equity | — | 362.5M | 617.8M | 707.4M | 852.6M | 33.0% | — | — | — | — |
| Op CF | — | -188.2M | -214.2M | -375.9M | -407.3M | — | -414.3M | — | — | — |
| Inv CF | — | -0.2M | -0.4M | -0.8M | -8.0K | — | — | — | — | — |
| Fin CF | — | 70.9M | 472.4M | 454.5M | 595.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMVT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMVT | Immunovant, Inc.(you) | $8.5B | 21 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | 21 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| CYTK | Cytokinetics, Incorporated | $10.0B | 22 | Sell |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 24 | Sell |
| SRRK | Scholar Rock Holding Corporation | $7.0B | 19 | Strong Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 28 | Sell |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 25 | Sell |
| CGON | CG Oncology, Inc. | $6.6B | 17 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%